INVEST IN METRIC MEDICAL DEVICES, INC. TODAY!
Our founders are highly successful serial entrepreneurs who design implants to promote healing and decrease complications in orthopedic extremity injuries. These implants treat fractures and deformities to improve patients' lives.
The orthopedic extremity reconstruction market is projected to reach $6.5 billion, globally, by 2030 at a CAGR of 6.3%. The foot and ankle lower extremity segment, our primary focus, is predicted to experience the largest CAGR of 8.9% from 2021 to 2030 and start with the surgical backlog created by the Covid-19 pandemic.*
During development and market trials, our current products generated over $10.5 million in revenue and we have two new next-generation products ready for full launch. We are currently developing our most disruptive product so far, The LINK™, a small bone-compressing external fixator. The market for minimally invasive surgical techniques is growing and is estimated to reach $94.4 billion by 2030 at a CAGR of 4.7%.**
Metric is focused on creating innovative technology and products to address the serious and persistent issue in musculoskeletal healthcare of deformity correction, fracture repair, and delayed bone healing. We've developed implants that fixate bone fractures and apply forces to the bone to improve healing. Our SuperStaple™ is in-market, our SuperSTEP™ staple and SuperScaffold™ hammer toe implant are FDA cleared for the market, and we are in the process of developing a new product, the LINK™.
The LINK™ is a minimally invasive external fixation device that is not only compelling in its technology but has the potential to revolutionize how bone fractures are treated. We are designing the LINK™ to allow physicians to treat more patients in their offices because the LINK™ will reduce the need for open surgery. As a result, we believe patients treated with the LINK™ will be able to receive faster care with reduced healthcare costs while adding significant value to the physician's practice.
The Problem & our Solution
Current treatment methods for osteoarthritis, deformities such as bunions, and small bone fractures, often involve open surgery and have high complication rates ranging from 13-56% (Source). Utilizing NASA’s discovery that a lack of mechanical loading degrades bone, our bone fixation implants change shape to provide compression to improve patient outcomes.
Our upcoming disruptive product, the LINK™, takes this even further. The LINK™ will provide all of the biomechanical and bone-compressing properties proven by our founders and validated through clinical experience, using a revolutionary patent pending external fixation system. We believe our proprietary, minimally-invasive approach will allow for many bony procedures in the foot, ankle, and hand to be performed in-office and without open-surgery. We are prepared to create a business shift from hospital to physician's offices, resulting in earlier treatments, reduced costs, and fewer complications.
*The image animation above on the left is a computer-generated rendering of a future product, the Link™, for functional demonstration purposes. The image above on the right is a pre-production photograph of the Link™. The product is still currently under development and is not yet available on the market.
The Market & our traction
The orthopedic extremity reconstruction market is projected to reach $6.5 billion, globally, by 2030 at a CAGR of 6.3%. The foot and ankle lower extremity segment, our primary focus, is predicted to experience its largest CAGR of 8.9% from 2021 to 2030, owing to baby boomer needs and patients increased awareness about the benefits of lower extremity reconstruction devices. Metric has established initial U.S. distribution of its products and seeks StartEngine investors to help drive value through building a growing and effective sales force.
During product development, we have generated $10.5 million in sales, with a gross profit exceeding 85%. Our technologies are protected by 13 patents in the U.S. with others issued in the UK, Germany, and France, as well as additional patents pending. We have multiple new products ready for full market launch, including the SuperSTEP™ staple and SuperScaffold™ hammer toe implant. Recently, multiple leading physicians have joined us as advisors to develop and advocate for our upcoming product, the LINK™.
Metric's founders have built a bone-compressing staple company and sold it with a strong return to its investors. Now, we envision Metric Medical Devices to keep building on this experience, launching a broad range of implants to dominate the orthopedic extremity market with minimally-invasive bone compressing products. With next-generation products in hand and disruptive technologies in the pipeline, we believe we are well-equipped and in a position to make that happen.
We have the innovative, patented technology and proven sales record to bring shareholder value in this fast-growing, multi-billion dollar orthopedic extremity market. Join Metric® as we provide improved minimally invasive care to patients around the world.
Metric Medical Devices, Inc., designs and sells innovative minimally invasive products and technologies for the orthopedic extremity market. Our mission is to become leaders in transforming the musculoskeletal repair standard of care, through the development and commercialization of bone fixation implants that actively change shape to compress the bone to stimulate bone growth and enhance healing.
Dr. Fox conducted pioneering research in bone healing and osteoporosis while at Southwest Research Institute, The University of Texas Health Science Center at San Antonio, and the Texas Biomedical Research Institute and made this a foundational element in two of the companies he founded, BioMedical Enterprises, Inc. (BME) and Agile Manufacturing, Inc. Building products and infrastructure with contract service and Federal, State, and County grant revenue he lead BME in the introduction and establishment of the U.S. market for shape-changing bone-compressing nitinol staples. This success resulted in the sale of BME to Depuy/Synthes, Johnson & Johnson Companies.
A prolific inventor he has had over 35 patents issued in the U.S. and Europe and published tens of articles. Skilled at medical product development, he and his teams have received 20 FDA clearances to market and commercialized the orthopaedic products stemming from his inventions. He has held engineering, advisory board, and adjunct faculty positions over the last 30 years at the institutions listed above as well as the University of Texas at Austin and the University of Alabama, Birmingham.
Dr. Fox founded and leads Metric Medical Devices, Inc. to broaden and advance the shape-changing bone-compressing orthopaedic implants he pioneered at BME. These next-generation nitinol staples and finger and toe fixation implants enter the market Dr. Fox established. These products are being followed by a disruptive minimally invasive external bone fixator based on these same implant shape-changing concepts. This LINK™ External Fixator will allow bone fixation and compression without open surgery. This is a disruptive concept in bone fixation and may, due to its minimally invasive technique, allow surgeons to treat more bone fractures in their office versus the hospital.
Dr. Fox and his wife Nancy are 37-year residents of San Antonio and native Texans. During his career, he was recognized in 1998 as Ernst & Young’s Entrepreneur of the Year and in 2005 as a Star of Innovation by the San Antonio community. In 2018 he was honored by the University of Texas at Austin’s Cockrell School of Engineering with the highest honor it bestows on its alumni, the Distinguished Alumni Award, and in 2019 he was inducted into the Department of Mechanical Engineering’s Academy of Distinguished Alumni. Dr. Fox is a registered Professional Engineer in the State of Texas and has spent his entire career focused on the orthopaedic problem and entrepreneurism.
Chief Financial Officer
Ms. Fox, co-founder, has over 30 years in the medical device industry. She has received awards and a BBA in Accounting at the University of Texas at San Antonio and focuses on operations including managing production, facilities, inventory, shipping/receiving, customer service and human resources. During her almost two decades as CFO of BioMedical Enterprises, Inc. she managed ISO/GMP quality systems, US and International medical product distribution, obtaining the CE mark and managed FDA, ISO and UL systems & audits.
Dr. Gary Frashier
Director, Board of Directors
Prior to OSI, Dr. Frashier served as President, International, and Executive Vice President of Millipore Corporation; President and CEO of Waters Corporation, the leader in liquid chromatography; President of Loctite Corporation’s Americas Group; and CEO of Genex Corporation, a protein engineering company, and Continental Water Systems, Inc. He has participated as a founder of Merrimack Pharmaceuticals, Inc (NASDAQ); Eutropics, Inc; America Stem Cells, Inc; Apex BioVentures Acquisition Corporation; LikeMinds, Inc.; and Xeras, Inc. He currently serves on the boards of several life science companies, including: LikeMinds, Inc., a private radiochemistry imaging company; Xeras, Inc., a private medical device company with products for improving the outcomes of knee replacement surgery; Metric Medical Devices, Inc, a developer and marketer of orthopedic fixation devices. Dr. Frashier has previously served on the Boards of numerous other private and public life science companies, including Maxim Pharmaceuticals, Inex Pharmaceuticals (Canada), Tanox, Inc., Cytoclonal Pharmaceuticals Co.; Exegenics Pharmaceuticals. Inc.; and Aderis, Inc. He is also a Strategic Partner in two of SV Venture funds. He was one of the founders of the New York Biotechnology Association and was selected as the “Long Island Businessman of the Year” by the Wharton Club. Dr. Frashier is an Advisory Trustee of the Southwest Research Institute, and he is chairman of the Chemical Engineering Advisory Board at the University of Texas at San Antonio, and serves on the Board of BioMed SA.
He was recognized by Texas Tech University as a Distinguished Engineer, where he received a B.S. in chemical engineering, and by the Massachusetts Institute of Technology as an Alfred P. Sloan Fellow, where he earned an MBA. He also earned a Ph.D. in innovation leadership from Our Lady of the Lake University. Dr. Frashier is a Registered Professional Engineer in Texas, and he previously served as a First Lieutenant in the U. S. Army Chemical Corps.
Mr. Jamie Grooms
Director, Board of Directors
Dr. Walter Simmons, III
Director, Board of Directors
Vice President Sales
National Sales Manager
Customer Service Manager
Engineering and Production Manager
Engineer Product Development and Testing
Dana Mecke has over 10 years of R&D and product development experience in the medical device industry. She holds a M.S. in biomedical engineering from the University of Texas Health Science Center and a B.S. in mechanical engineering from the University of Texas at San Antonio.
Quality and System Administrator
Enrique L. Rosario Aloma, DPM, Ph.D
He completed his Doctor of Podiatric Medicine degree from Barry University and performed his postgraduate work through Barry University’s Mercy Hospital Foot and Ankle Residency Program where he served as resident physician and chief resident.
Dr. Rosario Aloma started working at Barry University School of Podiatric Medicine as Adjunct Professor of Immunology and Microbiology. He is now Assistant Professor at the Barry University School of Podiatric Medicine, Foot and Ankle Institute. He has been published multiple times in Podiatry Institute. His current research, in collaboration with colleague Dr. Luis Rodriguez, is in the field of regenerative medicine and stem cell therapies.
Al D'Angelantonio, DPM, FACFAS
Conditions managed include foot and ankle sports injuries, trauma, fractures and sprains, tendonitis, cartilage injuries, skin disorders, heel pain, ganglion cysts, flat feet and arch disorders, arthritis, hammertoes, gait and walking disorders, foot and ankle deformities, and much more.
Dr. D’Angelantonio is an Internationally known expert in Foot and Ankle Surgery. Prior to becoming President and Chief Medical Officer of Integrated Foot and Ankle Specialists, Dr. Albert D’Angelantonio III was at Penn Medicine as Assistant Professor of Surgery in the Division of Plastic and Reconstructive Surgery, where he provided outstanding care from 2012-2022.
Dr. D’Angelantonio was the first faculty member at Penn Medicine with dedicated expertise in foot, ankle and lower leg reconstruction, and became Fellowship Director to share his knowledge and extensive experience with trainees. He got his advanced training as the very first fellow to complete a dedicated lower extremity fellowship within the Division of Plastic Surgery of Penn Medicine at the Hospital of the University of Pennsylvania. His training focused on providing patients with both functional and aesthetic outcomes for all conditions of the foot, ankle, and lower leg. Dr. D’Angelantonio actively educates surgeons from around the world each year. In fact, he is THE foot and ankle surgeon to other surgeons and their families.
He has been recognized:
As one of America's Top Foot and Ankle Surgeons, 2012 - 2021 by the Consumers Research Council of America,
By Best Doctors in America, 2012 - 2021,
By South Jersey Magazine as Top Doctor, 2017 - 2021,
As a Penn Medicine Health Care Hero, 2013 - 2021
Lindsay Barth, DPM
Residency: Deaconess Incarnate Word Health System, St. Louis, MO 1997
Board Certified: American Board of Podiatric Surgery since 2000
Dr. Barth is President and Founder of Next Step Foot & Ankle Centers. He is a leader in Advanced Foot and Ankle Surgical Techniques.
Dr. Lindsay Barth received his podiatric medical degree at Des Moines College of Podiatric Medicine and Surgery in Des Moines, Iowa. His surgical podiatric residency was completed at Deaconess Hospital in St. Louis, Missouri.
President and founder of Next Step Foot & Ankle Centers, Dr. Barth has been practicing podiatric medicine since 1996. He has been board certified by the American Board of Foot and Ankle Surgery since 2000, and is a leader in Advanced Foot and Ankle surgical techniques. Dr. Barth is a member of the Missouri Podiatric Medical Association, Missouri State Insurance Advisory Board, American Board of Foot and Ankle Surgery, and the American Podiatric Medical Association. Dr. Barth also serves as Chairman of the Political Action Committee.
Dr. Lindsay Barth performed the 1st Wright INBONE total ankle replacement surgery in September of 2007. He is one of the only physicians to offer total ankle replacement services in the St. Louis metro area.
Throughout the Midwest Dr. Barth provides lectures about Podiatric Surgery and Medicine to his peers and students. He is also actively involved in teaching the residents and students at DePaul Hospital. In addition to his position as senior partner of Next Step Foot & Ankle Centers, Dr. Barth has an interest in Walk Healthy Foot Care Products and Medical Spas.
Dr. Barth is an accomplished musician and is a frequent attendee of the St. Louis Symphony. In his spare time, you can find Dr. Barth renovating his 19th century historic home in St. Louis, boating, bicycling, hiking, and gardening.
Dr. Alan Block, DPM, MS, FASPS, FACFAS
1978-1980 University of Tennessee, Knoxville, Tennessee
1980-1982 The Ohio State University, Bachelor of Science, Columbus, Ohio
1982-1986 Ohio College of Podiatric Medicine, Doctor of Podiatric Medicine, Cleveland, Ohio
1987-1988 California College of Podiatric Medicine, Master of Science , University of Southern California, Los Angeles, California
1987-1988 1st Year Podiatric Residency, Circle City Hospital, Corona, California, Robert Parker, DPM
1988-1989 Advanced Ankle Surgery & Sports Medicine, Fellowship, Hayward Foot and Ankle Clinic, Hayward, California, Steven I. Subotnick, DPM, MS
1989-1990 2nd Year Podiatric ResidencyMedical Center Hospital, Portland, Oregon, John Mozena, DPM, Residency Director
1997 The American Board of Foot and Ankle Surgery, American Council of Certified, Podiatric Physicians and Surgeons
The State of Ohio
The State of South Carolina
The State of California (Inactive)
Palmetto State Surgical Podiatry Associates
Christopher Bromley, DPM
Dennis Martin Chaney, DPM
University of Northern Iowa
BS, Biology, Chemistry
Training: Reconstructive Rearfoot and Ankle Fellowship, West Houston Medical Center, Foot and Ankle Surgical Residency, West Houston Medical Center
Dr. Chaney earned his Doctor of Podiatric Medicine (DPM) degree at Des Moines University. He then completed a two-year foot and ankle surgical residency at the West Houston Medical Center in Houston Texas. Dr. Chaney finished his training in Houston by completing a one-year reconstructive Rearfoot and Ankle Fellowship.
Dr. Chaney is board certified in both foot surgery and reconstructive rearfoot and ankle surgery by the American Board of Foot & Ankle Surgery. He has authored numerous papers regarding foot and ankle surgery. He also regularly speaks at regional and national scientific meetings on foot and ankle surgery. Dr. Chaney has served on numerous committees for the American College of Foot & Ankle Surgeons and the American Board of Foot & Ankle Surgery.
Dr. Chaney is involved in residency training as clinical adjunct faculty for the University of Texas Health Science Center at San Antonio.
He specializes in surgical and non-surgical care of all aspects of foot and ankle care including deformity, injuries, sports medicine, diabetes, wound care, dermatology, arthritis and trauma.
Dr. Chaney also specializes 3D Correction for the surgical correction of bunions. This method uses cutting-edge medical instrumentation and fixation to correct your bunion and significantly reducing your likelihood of a recurring bunion.
Coleman Clougherty, DPM
Residency - St Vincent Charity Hospital
Cleveland, OH USA 2015
Medical Education - Ohio College of Podiatric Medicine (Kent State College of PM)
Independence, OH USA 2012
Foot and Ankle Surgery - Foot Surgery
Foot and Ankle Surgery - Reconstructive Rearfoot and Ankle Surgery
Amram Dahukey, D.P.M., FACFAS
American Board of Podiatric Surgery, Board Certified in Foot & Ankle Surgery
Fellow, American College of Foot & Ankle Surgeons
Past Director and Founder, TMC and Midwestern University School of Podiatric Medicine Residency Program in Foot and Ankle Surgery.
Dr. Dahukey is the Co - Past Director and founder of S.A.L.T (Save a Limb Tucson) program at Tucson Medical Center
Director, Sahuaro Research Institute, PLLC
Adjunct Associate Professor Midwestern University College of Health Sciences
Hospital Affiliations:Tucson Medical Center, St. Mary's Hospital, Tucson, Tucson Surgery Center, Northwest Hospital, Tucson
BA, Boston University, Boston MASS BJ Ed Hebrew College Boston Mass DPM, Kent State University College of Podiatric Medicine, Kent OH, Residency, Veterans Affairs Medical Center, Tucson AZ, Professional Memberships Fellow, American College of Foot and Ankle Surgeons Diplomate, American Board of Foot and Ankle Surgery
Personal and professional interests
Dr. Amram Dahukey is the founder and chairman of Premier Foot & Ankle Surgeons. He was born in Jerusalem, Israel. Following completion of his medical education, he attended many post graduate courses and received certification in laser surgery, Ankle Arthroscopy and Endoscopic Surgery. Dr. Dahukey has been awarded Master Surgeon for HyProCure procedure for flat feet, a minimally invasive procedure for correction of flat foot deformity.
Dr. Dahukey is the founder and Past Director of Tucson Medical Center and Midwestern University Podiatric Residency Program, a three year training program in Foot and Ankle Surgery currently trianing nine residents in foot and ankle surgery. He is also the past Director of Save a Limb Tucson (S.A.L.T) program at Tucson Medical Center. Dr. Dahukey is past President of the Arizona Podiatric Medical Association. He is past chairman of the section of Podiatric Surgery at St. Mary’s Hospital, and Tucson Medical Center. Dr. Dahukey is past secretary-treasurer of Arizona State Physician Association. He currently serves on The Pima County Medical Society Board of Directors.
Dr. Dahukeys professional interests include reconstructive foot and ankle surgery, ankle arthroscopy, joint replacement, preventive surgical intervention for diabetic wounds, laser surgery, ingrown toenail, bunion and hammertoe surgery. Dr. Dahukey has been in private practice in Southern Arizona for over 30 years. He is married with two children.
Christopher Edward Gross, MD
Philip R. Jenkins, DPM
Foot and Ankle Surgery, Board Certified
Jason Miller, DPM
Dr. Miller began his career in 2001 teaching in the Department of Surgery at the Temple University School of Podiatric Medicine where he served as Residency Director of the Temple University Health Systems/Northeastern Hospital podiatric residency program and Chief of the section. In 2002, Dr. Miller was honored in the Temple University “Gallery of Success”, an annual prestige that is awarded to a recent and past Temple graduate who has excelled in their chosen career. Dr. Miller continues to hold the rank of Associate Professor as an adjunct faculty member in the Dept. of Surgery at TUSPM. He has been chosen as a Top Doc multiple times in Philadelphia and Main Line Today magazines.
Dr. Miller has written numerous articles in several peer-reviewed journals, presented many poster abstracts at national meetings, written and edited chapters in board review books and lectures both nationally and internationally on a variety of topics related to foot and ankle surgery. He currently serves on the editorial board of the Journal of Foot & Ankle Surgery and The Foot and Ankle Journal Online.
The PA Intensive Lower Extremity Fellowship program was founded by Dr. Miller in 2011 and was recognized by the American College of Foot & Ankle Surgeons as the nation’s first 2 year foot & ankle post-graduate training program. In 2013, he formed a new 3-year residency program at Phoenixville Hospital to serve the community and provide training opportunities for graduating DPM students nationwide.
Naohiro Shibuya, DPM, MS, FACFAS
School of Podiatric Medicine in Philadelphia and received his Master of Science in
Clinical Investigation from the University of Texas Health Science Center at San
Antonio’s School of Biomedical Sciences. Dr. Shibuya is a Fellow of the American
College of Foot and Ankle Surgery. He was recently appointed Clinical Professor
University of Texas Rio Grande Valley, Edinburg Texas and has been affiliated with
Texas A&M University System Health Science Center, Baylor Scott & White Medical
Center and the Veteran’s Hospital, Temple TX.
Board Certified in Reconstructive and Rearfoot and Ankle Surgery (ABFAS)
Board Certified in Foot Surgery (ABFAS)
Editor-in-Chief, Journal of Foot and Ankle Surgery
Scientific Chairman, Annual Meeting of the American College of Foot and Ankle
Member Texas Podiatric Medical Association, Continuing Medical Education
Member Faculty, AO North America
Member Scientific editor, Weekly@eACFAS
Member Part III National Podiatric Board Examination Item Writing Committee
Areas of Interest
Foot and Ankle Arthritis Care, Diabetes-Related Foot Conditions, Complete Bunion and
Hammertoe Correction, General and Complex Fracture Repair, Minimally Invasive Foot
and Ankle Surgery
3rd Place Award, The Effect of Cryotherapy Devices in the Post-Operat
OPMA 88th Annual Scientific Seminar Resident Paper Finalist competition
ACFAS 2012, 2011 Annual Scientific Conference, Manuscript Finalist
2012 - Manuscript, 3rd Place Award, Incidence of Acute Deep Vein Thromb,
ACFAS Annual Scientific Conference
2005 - 63rd ACFAS Annual Meeting and Scientific Seminar, Manuscript Finalist
James D. Sills-Powell, DPM, MBA, MS
Dr. Sills-Powell treats all medical and surgical conditions of the foot and ankle. He has a special interest in wound management, limb salvage and preservation, trauma, and reconstructive foot and ankle surgery.
He is a member in good standing with the APMA (American Podiatric Medical Association) and the APPMA (American Podiatric Practice Management Association). More Than Just Podiatry is also a member of the Western St. Charles County Chamber of Commerce.
Sudheer Reddy, M.D.
After receiving his undergraduate degree, Dr. Reddy earned his medical degree at Albany Medical College, in Albany, New York. He was welcomed as a Junior year member into the Alpha Omega Alpha Medical Honor Society. Dr. Reddy then completed a surgical internship and orthopaedic surgery residency at the Hospital of University of Pennsylvania, in Philadelphia, Pennsylvania.
After finishing his residency, Dr. Reddy completed advanced fellowship training in orthopaedic sports medicine at the University of California-San Francisco, as well as foot and ankle orthopaedic surgery at the Oakland Bone and Joint Center, in Oakland, California.
Dr. Reddy is board-certified by the American Board of Orthopedic Surgery. Additionally, he is a fellow of the American Academy of Orthopaedic Surgeons, and an active member of the American Orthopaedic Foot and Ankle Society.
When Dr. Reddy is not seeing patients, he enjoys traveling, reading about history, and playing tennis.
Thomas Sanders, MD
Dr. Sanders attended the University of Virginia in Charlottesville for his bachelor's degree and then earned his medical degree and completed his residency at Georgetown University in Washington, DC. During his final year of residency, he served as the administrative chief resident and earned the Hugh. H. Hussey award for excellence in teaching by Georgetown University School of Medicine twice.
After completing his residency, Dr. Sanders went on to complete a fellowship in foot and ankle surgery/lower extremity trauma and reconstruction at the Florida Orthopaedic Institute in Tampa. He received additional, specialized training for both surgical and non-surgical treatments of foot and ankle injuries and diseases, including total ankle arthroplasty. During both his residency and fellowship, Dr. Sanders treated elite level professional, Olympic and collegiate athletes.
Outside of his work at Orthopaedic Foot & Ankle Center, Dr. Sanders is an assistant professor at Georgetown University Medical Center in Washington, DC, and a member of both the American Academy of Orthopaedic Surgeons and American Orthopaedic Foot and Ankle Society.
Daniel Scott, MD, MBA
Jason M Sweeley, DPM
Dr. Sweeley has advanced training in reconstructive foot and ankle surgery as well as diabetic limb salvage along with training in biomechanical issues and sports medicine. He has completed a micro-vascular surgery course at the Cleveland Clinic and incorporates this training into his surgical approach to neurosurgery including tarsal tunnel decompression. His primary clinical interests include podiatric sports medicine, tarsal tunnel decompression, and rearfoot pathology. His treatment philosophy combines surgical approaches with conservative and non-surgical strategies to restore foot and ankle health and function in both children and adults.
Dr. Sweeley is a Fellow of the American College of Foot and Ankle Surgeons and a member of the American Podiatric Medical Association and the Pennsylvania Podiatric Medical Association.
Maximum Number of Shares Offered subject to adjustment for bonus shares
Most Recent Fiscal Year-End
Prior Fiscal Year-End
Cash & Cash Equivalents
Revenue & Sales
Costs of Goods Sold
Metric Medical Devices, Inc.
846 Silver Springs, Helotes, TX 78063
Minimum Investment Amount
Minimum Number of Shares Offered
Maximum Number of Shares Offered
Price per Share
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Previous investors in Metric Medical will receive an additional 5% bonus shares if they invest in this raise.
All Investors shall receive the Incentive, upon request, of being introduced to Physicians who use Metric Medical Device, Inc. products.
Community Super Early Birds
Invest within the two weeks and receive 20% bonus shares
Super Early Bird Bonus
Invest within the first three weeks and receive 15% bonus shares
Early Bird Bonus
Invest within the first four weeks and receive 10% bonus shares
Invest within the first five weeks and received 5% bonus shares
5% bonus shares
8% bonus shares
10% bonus shares, access to the Linkedin private discussion group.
15% bonus shares, access to the Linkedin private discussion group.
$25,000+ Elite Benefactors
20% bonus shares, Video Meeting with Founding Team, and access to the Linkedin private discussion group.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
*Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
The 10% StartEngine Owners' and Incentive Bonus
Metric Medical Devices, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.15 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $115. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
This is it! This is your last chance to invest for Metric’s equity offering ends at 11:59 PDT TODAY.
To all those who have followed us along our crowdfunding raise and joined our team at Metric we thank you! With plenty of momentum heading into Q2 we are encouraged and excited for continued developments of The LINK™ and success with Metric.
As the closing window approaches tomorrow, invest now to become an owner in Metric.
Metric would like to welcome three additional Physician Advisors to our LINK™ development team. Their roles are both technical in refining the LINK™ design and clinical in developing the surgical technique and clinical uses.
James B. Cahill, DPM - https://www.cahillpodiatryteam.com/
Marie Williams, DPM - https://southfloridafootandankle.com/
Raafae Hussain, DPM - https://www.completefootandanklecare.com
See what Dr. Fox had to say about Metric and product development on our recent webinar.
INVEST NOW. Do not miss your chance to become an owner of Metric as we strive to make advancements to orthopedic bone fixation implants to better quality of life for children, middle aged adults, and the elderly.
On April 28th Dr. Casey Fox will be inducted into the Department of Biomedical Engineering Academy at The University of Texas at Austin in its inaugural year. This Academy honors the Department’s Alumni for their contributions to the biomedical engineering field, healthcare, The University and Department.
INVEST NOW. Join Dr. Fox and other owners of Metric as we strive to ease healthcare challenges.
Our LIVE Investor Q&A with Metric CEO, Casey Fox is TODAY. Join us and hear what he has to say about our company and our product developments.
Webinar starts this morning at 11am CDT, reserve your spot by clicking here or the image below.
As we are in the final stretch of our raise we encourage you to catch our LIVE Investor Q&A tomorrow with Metric CEO, Casey Fox.
Click here to sign up the webinar.
ONLY 8 days remain in our live raise! We want to offer our followers another Q&A Webinar. Post your questions to our discussion board so we can answer them March 16th, 2023 at 11am CDT.
Click to Sign up to attend our upcoming webinar.
To ease access to yesterday's webinar we wanted to provide another link.
Click the link, https://youtu.be/xeLX3jq8n9Y to see the Webinar and return to StartEngine to INVEST.
Please submit any additional questions you might have for the Metric team.
In case you were unable to attend the Investor Webinar this morning we have you covered.
Check out what Dr. Fox had to say!
Members get an extra 10% shares in addition to rewards below!
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
5% bonus shares
8% bonus shares
10% bonus shares, access to the Linkedin private discussion group.
15% bonus shares, access to the Linkedin private discussion group.
20% bonus shares, Video Meeting with Founding Team, and access to the Linkedin private discussion group.
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.